Structure Therapeutics (NASDAQ:GPCR) versus Liquidia (NASDAQ:LQDA) Critical Comparison

Structure Therapeutics (NASDAQ:GPCR) and Liquidia (NASDAQ:LQDA) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Structure Therapeutics and Liquidia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	1	12	3	2.89
Liquidia	2	1	5	3	2.82

Structure Therapeutics presently has a consensus target price of $110.55, suggesting a potential upside of 114.07%. Liquidia has a consensus target price of $68.88, suggesting a potential downside of 3.28%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than Liquidia.

Institutional & Insider Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Structure Therapeutics and Liquidia”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20 million	($0.87)	-59.36
Liquidia	$158.32 million	40.00	-$68.92 million	$0.14	508.64

Liquidia has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Structure Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Structure Therapeutics and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Liquidia	7.74%	46.82%	7.06%

Summary

Liquidia beats Structure Therapeutics on 9 of the 13 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.